JP7046828B2 - 滲出型加齢性黄斑変性の治療のための組成物 - Google Patents

滲出型加齢性黄斑変性の治療のための組成物 Download PDF

Info

Publication number
JP7046828B2
JP7046828B2 JP2018554334A JP2018554334A JP7046828B2 JP 7046828 B2 JP7046828 B2 JP 7046828B2 JP 2018554334 A JP2018554334 A JP 2018554334A JP 2018554334 A JP2018554334 A JP 2018554334A JP 7046828 B2 JP7046828 B2 JP 7046828B2
Authority
JP
Japan
Prior art keywords
seq
itr
vector
eye
raav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018554334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518427A5 (enExample
JP2019518427A (ja
Inventor
トレティアコバ，アナ・ピー
ウイルソン，ジェームス・エム
Original Assignee
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア filed Critical ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Publication of JP2019518427A publication Critical patent/JP2019518427A/ja
Publication of JP2019518427A5 publication Critical patent/JP2019518427A5/ja
Priority to JP2022046261A priority Critical patent/JP7111924B2/ja
Application granted granted Critical
Publication of JP7046828B2 publication Critical patent/JP7046828B2/ja
Priority to JP2022116098A priority patent/JP7492556B2/ja
Priority to JP2024080598A priority patent/JP2024105617A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018554334A 2016-04-15 2017-04-14 滲出型加齢性黄斑変性の治療のための組成物 Active JP7046828B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022046261A JP7111924B2 (ja) 2016-04-15 2022-03-23 滲出型加齢性黄斑変性の治療のための組成物
JP2022116098A JP7492556B2 (ja) 2016-04-15 2022-07-21 滲出型加齢性黄斑変性の治療のための組成物
JP2024080598A JP2024105617A (ja) 2016-04-15 2024-05-17 滲出型加齢性黄斑変性の治療のための組成物

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662323184P 2016-04-15 2016-04-15
US62/323,184 2016-04-15
US201662331100P 2016-05-03 2016-05-03
US62/331,100 2016-05-03
US201762442946P 2017-01-05 2017-01-05
US62/442,946 2017-01-05
US201762460515P 2017-02-17 2017-02-17
US62/460,515 2017-02-17
US201762466721P 2017-03-03 2017-03-03
US62/466,721 2017-03-03
PCT/US2017/027529 WO2017180936A1 (en) 2016-04-15 2017-04-14 Compositions for treatment of wet age-related macular degeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022046261A Division JP7111924B2 (ja) 2016-04-15 2022-03-23 滲出型加齢性黄斑変性の治療のための組成物

Publications (3)

Publication Number Publication Date
JP2019518427A JP2019518427A (ja) 2019-07-04
JP2019518427A5 JP2019518427A5 (enExample) 2020-05-28
JP7046828B2 true JP7046828B2 (ja) 2022-04-04

Family

ID=59253994

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018554334A Active JP7046828B2 (ja) 2016-04-15 2017-04-14 滲出型加齢性黄斑変性の治療のための組成物
JP2022046261A Active JP7111924B2 (ja) 2016-04-15 2022-03-23 滲出型加齢性黄斑変性の治療のための組成物
JP2022116098A Active JP7492556B2 (ja) 2016-04-15 2022-07-21 滲出型加齢性黄斑変性の治療のための組成物
JP2024080598A Pending JP2024105617A (ja) 2016-04-15 2024-05-17 滲出型加齢性黄斑変性の治療のための組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022046261A Active JP7111924B2 (ja) 2016-04-15 2022-03-23 滲出型加齢性黄斑変性の治療のための組成物
JP2022116098A Active JP7492556B2 (ja) 2016-04-15 2022-07-21 滲出型加齢性黄斑変性の治療のための組成物
JP2024080598A Pending JP2024105617A (ja) 2016-04-15 2024-05-17 滲出型加齢性黄斑変性の治療のための組成物

Country Status (10)

Country Link
US (2) US11197937B2 (enExample)
EP (1) EP3452103A1 (enExample)
JP (4) JP7046828B2 (enExample)
KR (2) KR102574810B1 (enExample)
AU (2) AU2017248731B2 (enExample)
CA (1) CA3019426A1 (enExample)
IL (2) IL322403A (enExample)
MA (1) MA44873A (enExample)
SG (2) SG11201808426XA (enExample)
WO (1) WO2017180936A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR20200060456A (ko) * 2017-09-27 2020-05-29 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항-VEGF Fab를 이용한 안구 질환의 치료
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
AU2018372235B9 (en) * 2017-11-27 2022-03-10 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
JP2021506861A (ja) 2017-12-19 2021-02-22 アコーオス インコーポレイテッド 内耳への治療用抗体のａａｖ媒介送達
US20210093734A1 (en) * 2018-02-20 2021-04-01 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-realted macular degeneration
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
JP2022049718A (ja) * 2019-02-05 2022-03-30 アステラス製薬株式会社 アデノ随伴ウイルスを用いたｃｘ３ｃｌ１遺伝子の導入による網膜変性疾患の治療
CN113966236A (zh) 2019-04-03 2022-01-21 再生生物股份有限公司 眼睛病状的基因疗法
BR112021021156A2 (pt) * 2019-04-24 2022-02-08 Regenxbio Inc Terapêuticos anticorpos totalmente humanos pós-tradução modificados
WO2020243659A1 (en) * 2019-05-31 2020-12-03 University Of Florida Research Foundation, Incorporated Vector-based therapy for thyroid disease
WO2021041373A1 (en) 2019-08-26 2021-03-04 Regenxbio Inc. Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab
CN114728049A (zh) 2019-10-07 2022-07-08 再生生物股份有限公司 腺相关病毒载体药物组合物和方法
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021231491A1 (en) * 2020-05-11 2021-11-18 University Of Florida Research Foundation, Incorporated Disease correction by delivery of aav8 vectors expressing codon optimized naglu
TW202208622A (zh) * 2020-05-12 2022-03-01 賓州大學委員會 用於治療克拉培氏病之組成物
WO2021255589A1 (en) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof
WO2021255590A1 (en) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof
CN113952473A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
AU2021362770A1 (en) * 2020-10-16 2022-12-08 Gyroscope Therapeutics Limited Nucleic acid encoding an anti-VEGF entity and a negative complement regulator and uses thereof for the treatment of age-related macular degeneration
CN116528892A (zh) * 2020-10-28 2023-08-01 再生生物股份有限公司 用于眼部适应症的载体化抗TNF-α抗体
CN116457373A (zh) * 2020-10-29 2023-07-18 再生生物股份有限公司 用于眼部适应症的载体化TNF-α拮抗剂
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
EP4284335A1 (en) 2021-02-01 2023-12-06 RegenxBio Inc. Gene therapy for neuronal ceroid lipofuscinoses
AU2023215253A1 (en) * 2022-02-02 2024-09-19 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
AU2023250660A1 (en) 2022-04-06 2024-10-24 Regenxbio Inc. Pharmaceutical composition comprising a recombinant adenoassociated virus vector with an expression cassette encoding a transgene for suprachoroidal administration
IL319873A (en) 2022-09-30 2025-05-01 Regenxbio Inc Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB
WO2025073297A1 (zh) * 2023-10-06 2025-04-10 甘李药业股份有限公司 表达抗vegf融合蛋白的aav病毒载体及其用途
WO2025160405A1 (en) * 2024-01-24 2025-07-31 Duke University Compositions and methods for generation and secretion of aav particles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151341A1 (en) 2013-03-15 2014-09-25 The Trustees Of The University Of Pennsylvania Compositions and methods for treating mpsi
JP2015523060A (ja) 2012-05-15 2015-08-13 アバランチ オーストラリア プロプライエタリー リミテッド Ａａｖｓｆｌｔ−１を用いたａｍｄの処置
WO2015164778A1 (en) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennysylvania Ldlr variants and their use in compositions for reducing cholesterol levels
WO2015175639A1 (en) 2014-05-13 2015-11-19 The Trustees Of The University Of Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL310327A1 (en) 1993-02-12 1995-12-11 Univ Leland Stanford Junior Adjustable transcription of target genes and other biological processes
CA2209183A1 (en) 1994-12-29 1996-07-11 Joel L. Pomerantz Chimeric dna-binding proteins
CA2219080A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamycin-based regulation of biological events
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
JP2003524368A (ja) 1997-08-26 2003-08-19 アリアド ジーン セラピューティクス インコーポレイテッド ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白
AU752129B2 (en) 1997-08-27 2002-09-05 Ariad Gene Therapeutics, Inc. Chimeric transcriptional activators and compositions and uses related thereto
AU755784B2 (en) 1998-01-15 2002-12-19 Ariad Pharmaceuticals, Inc. Regulation of biological events using multimeric chimeric proteins
CA2319492A1 (en) 1998-02-13 1999-08-19 President And Fellows Of Harvard College Novel dimerizing agents, their production and use
DE60039766D1 (de) 1999-08-09 2008-09-18 Targeted Genetics Corp Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
WO2001029242A2 (en) 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
CN1461342A (zh) 2000-07-26 2003-12-10 路德维格癌症研究所 糖基化vegf－b和增加可溶性vegf－b量的方法
CA2915124C (en) 2001-11-13 2018-08-14 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
ES2602352T3 (es) 2001-12-17 2017-02-20 The Trustees Of The University Of Pennsylvania Secuencias de serotipo 8 de virus adenoasociado (VAA), vectores que las contienen y usos de las mismas
WO2003068801A2 (en) 2002-02-11 2003-08-21 Genentech, Inc. Antibody variants with faster antigen association rates
US20040208847A1 (en) 2003-03-28 2004-10-21 Fabienne Rolling Method and vectors for selectively transducing retinal pigment epithelium cells
EP2298926A1 (en) 2003-09-30 2011-03-23 The Trustees of The University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
EP2357010B1 (en) 2005-04-07 2013-06-12 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
US7456683B2 (en) 2005-06-09 2008-11-25 Panasonic Corporation Amplitude error compensating device and quadrature skew error compensating device
CL2008003218A1 (es) 2007-10-30 2009-03-06 Genentech Inc Método para la purificación de un anticuerpo a partir de una composición que comprende el anticuerpo y al menos un contaminante.
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
KR101010352B1 (ko) 2008-05-30 2011-01-25 삼성중공업 주식회사 전력 제어 장치 및 방법
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
US8734809B2 (en) * 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
PE20120622A1 (es) 2009-06-17 2012-05-26 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US8663624B2 (en) * 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN107828820B (zh) 2010-10-27 2022-06-07 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
EP4234571A3 (en) 2011-02-10 2023-09-27 The University of North Carolina at Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
JP6091435B2 (ja) * 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
RS66184B1 (sr) 2011-04-22 2024-12-31 Univ California Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu
EP2559443A1 (en) 2011-08-16 2013-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
US20130090375A1 (en) * 2011-10-06 2013-04-11 Cornell University Virus-mediated delivery of bevacizumab for therapeutic applications
EP2847337A4 (en) 2012-05-09 2016-04-27 Univ Oregon Health & Science ADENO ASSOCIATED VIRUS PLASMIDS AND VECTORS
CA3240136A1 (en) 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US9567376B2 (en) 2013-02-08 2017-02-14 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
EP2970946A4 (en) 2013-03-13 2016-09-07 Philadelphia Children Hospital ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
JP6552511B2 (ja) 2013-10-11 2019-07-31 マサチューセッツ アイ アンド イヤー インファーマリー 祖先ウイルス配列を予測する方法およびその使用
HRP20211015T1 (hr) 2013-12-03 2021-10-01 Hookipa Biotech Gmbh Cjepivo protiv citomegalovirusa (cmv)
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
US9840553B2 (en) * 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10064752B2 (en) 2014-09-11 2018-09-04 Orbit Biomedical Limited Motorized suprachoroidal injection of therapeutic agent
CA2977355A1 (en) 2015-02-20 2016-08-25 University Of Iowa Research Foundation Methods and compositions for treating genetic eye diseases
CN108135994B (zh) * 2015-05-13 2022-01-25 宾夕法尼亚州大学信托人 Aav-介导的抗-流感抗体的表达及其使用方法
US20190292250A1 (en) 2015-08-31 2019-09-26 The Trustees Of The University Of Pennsylvania Aav-anti-vegf for treating cancer in companion animals
GB201519086D0 (en) 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
EP3400014A1 (en) 2016-01-08 2018-11-14 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
AU2017250797A1 (en) 2016-04-15 2018-10-25 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-VEGF fab
KR20200060456A (ko) 2017-09-27 2020-05-29 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항-VEGF Fab를 이용한 안구 질환의 치료
CN113966236A (zh) 2019-04-03 2022-01-21 再生生物股份有限公司 眼睛病状的基因疗法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015523060A (ja) 2012-05-15 2015-08-13 アバランチ オーストラリア プロプライエタリー リミテッド Ａａｖｓｆｌｔ−１を用いたａｍｄの処置
WO2014151341A1 (en) 2013-03-15 2014-09-25 The Trustees Of The University Of Pennsylvania Compositions and methods for treating mpsi
WO2015164778A1 (en) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennysylvania Ldlr variants and their use in compositions for reducing cholesterol levels
WO2015175639A1 (en) 2014-05-13 2015-11-19 The Trustees Of The University Of Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIMBERIS MARIA P; XIAO RU; MAGUIRE ALBERT M; ET AL，MOLECULAR THERAPY; 15TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-GENE-AND-CELL-THERAPY (ASGCT)，2012年05月01日，VOL:20, NR:SUPPL. 1，PAGE(S):S31，http://dx.doi.org/10.1016/S1525-0016(16)35879-8
Martin Lock ，Hum Gene Ther Methods，2014年，25(2)，115-125

Also Published As

Publication number Publication date
WO2017180936A1 (en) 2017-10-19
KR102574810B1 (ko) 2023-09-08
US20190381194A1 (en) 2019-12-19
JP2022084809A (ja) 2022-06-07
IL262207B1 (en) 2025-09-01
EP3452103A1 (en) 2019-03-13
AU2017248731A1 (en) 2018-10-18
US20220288238A1 (en) 2022-09-15
AU2024216307A1 (en) 2024-10-17
NZ746729A (en) 2023-08-25
CA3019426A1 (en) 2017-10-19
JP7492556B2 (ja) 2024-05-29
SG10201913159UA (en) 2020-02-27
US11197937B2 (en) 2021-12-14
JP2022141856A (ja) 2022-09-29
IL322403A (en) 2025-09-01
JP7111924B2 (ja) 2022-08-02
KR20230130765A (ko) 2023-09-12
MA44873A (fr) 2019-03-13
IL262207A (en) 2018-11-29
SG11201808426XA (en) 2018-10-30
JP2024105617A (ja) 2024-08-06
AU2017248731B2 (en) 2024-08-29
JP2019518427A (ja) 2019-07-04
KR20190031196A (ko) 2019-03-25

Similar Documents

Publication Publication Date Title
JP7111924B2 (ja) 滲出型加齢性黄斑変性の治療のための組成物
JP2024016207A (ja) 滲出型加齢性黄斑変性の治療のための組成物
Pavlou et al. Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders
JP6990667B2 (ja) 眼性新血管形成を低減するための組成物および方法
CN113966236A (zh) 眼睛病状的基因疗法
CN104994882A (zh) 使用aavsflt-1治疗amd
CN110423281B (zh) 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物
JP2022522776A (ja) 対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与
TW202235618A (zh) 治療眼內壓相關疾患
NZ787256A (en) Compositions For Treatment of Wet Age-Related Macular Degeneration
JPWO2022018516A5 (enExample)
NZ787237A (en) Compositions For Treatment of Wet Age-Related Macular Degeneration
NZ746729B2 (en) Compositions for treatment of wet age-related macular degeneration
WO2025103416A1 (zh) 用于老年相关性黄斑变性的治疗的基因治疗药物
Ferguson Regulation of gene expression for therapy of age related macular degeneration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220323

R150 Certificate of patent or registration of utility model

Ref document number: 7046828

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250